HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Lancet
Authors | |
Abstract | Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target. |
Year of Publication | 2014
|
Journal | Lancet
|
Date Published | 2014/09/24
|
ISSN | 0140-6736
|
DOI | 10.1016/S0140-6736(14)61183-1
|
PubMed ID | 25262344
|
PubMed Central ID | PMC4322187
|
Links |